TrialsgrambetaRCTs are beautiful
ESC Congress 2026Apresentado sáb., 29 de ago. · 11:15 GMT+2Hot Line 3Todos os ensaios Hot Line →

PREMIUM

2026

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction (PREMIUM)

In 2,216 patients with STEMI undergoing primary PCI, aspirin-free prasugrel monotherapy was not non-inferior to 12 months of dual antiplatelet therapy for death, myocardial infarction or stroke at 12 months.

Resultado

Eficácia: Composite of all-cause death, myocardial infarction or stroke at 12 months (non-inferiority)HR 1,34 (IC 95% 1,02-1,75) · P = 0,40

Segurança: Major bleedingHR 0,66 (IC 95% 0,47-0,91)

Abaixo de 1 a favor de aspirin-free prasugrel monotherapy, acima de 1 a favor de 12 months of dual antiplatelet therapy.

Taxas de eventos Aspirin-free prasugrel monotherapy 11,0% vs. 12 months of dual antiplatelet therapy 8,5% (composite of all-cause death, myocardial infarction or stroke at 12 months (non-inferiority))

Também relatado: Non-inferiority not met. Definite or probable stent thrombosis and serious adverse events were similar.

Publicação original
Subtema
Aspirin-free antiplatelet strategy
Desenho
Investigator-initiated, multicentre, open-label randomised controlled trial in Japan; 1:1 randomisation before primary PCI; all patients receive platinum-chromium everolimus-eluting stents (SYNERGY) with routine intravascular imaging guidance; non-inferiority design for the primary endpoint; 12-month follow-up
Relevância
Importante: um de vários pilares.
Fonte
Takahashi K, Kozuma K, Morino Y, et al. N Engl J Med. 2026; published online 29 August.doi 10.1056/nejmoa2606997

Discussão e crítica

Dropping aspirin from the start of primary PCI failed its non-inferiority test, and the confidence interval sits entirely above 1: 2.5 percentage points more death, stroke or infarction, bought for 2.8 points less major bleeding. That is a trade, not a free lunch, and the trial was not designed to say which side a given patient should take. Japanese, open-label, and run with the low prasugrel dose used in Japan rather than the Western regimen, so the ischaemic arm of the trade may not transfer directly.